PMID- 29364584
OWN - NLM
STAT- MEDLINE
DCOM- 20181217
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20 Suppl 1
DP  - 2018 Feb
TI  - A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized 
      controlled trials.
PG  - 34-46
LID - 10.1111/dom.13135 [doi]
AB  - The first clinical study to investigate effects of dipeptidyl peptidase-4 (DPP-4) 
      inhibition was published in 2002, and since then, numerous randomized controlled 
      trials (RCTs) have shown that DPP-4 inhibitors are efficacious, safe and 
      well-tolerated. This review will focus upon RCTs which have investigated DPP-4 
      inhibitors in patient groups which are often under-represented or excluded from 
      typical phase 3 clinical trials. Large cardiovascular (CV) safety outcome trials 
      in patients with established CV disease have confirmed that DPP-4 inhibitors are 
      not associated with any additional CV risk in these already-at-high-risk 
      individuals, while raising awareness of any uncommon adverse events, such as 
      heart failure hospitalization seen in one of the trials. Studies in patients with 
      kidney disease have shown DPP-4 inhibitors to be efficacious without increasing 
      the risk of hypoglycaemia, irrespective of the degree of renal impairment, while 
      data from the large CV trials as well as smaller RCTs have even pointed towards 
      potential renoprotective effects such individuals. The use of DPP-4 inhibitors 
      with insulin when therapy requires intensification may be beneficial without 
      affecting the incidence or severity of hypoglycaemia, with these effects also 
      being replicated in patients with chronic kidney disease, for whom other agents 
      may not be suitable. Attention is now turning towards exploring the potential 
      utility of DPP-4 inhibitors in other circumstances, including for in-hospital 
      management of hyperglycaemia and in other metabolic disorders. Together, these 
      RCTs raise the possibility that in the future, DPP-4 inhibitors may have a 
      broader use which may extend beyond glycaemic control in the typical type 2 
      diabetes mellitus (T2DM) patient seen in general practice and may encompass 
      conditions other than T2DM.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Deacon, Carolyn F
AU  - Deacon CF
AUID- ORCID: 0000-0003-2611-5642
AD  - Department of Biomedical Sciences, Panum Institute, University of Copenhagen, 
      Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - dipeptidyl peptidase-4
OT  - incretin therapy
OT  - type 2 diabetes
EDAT- 2018/01/25 06:00
MHDA- 2018/12/18 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/09/27 00:00 [received]
PHST- 2017/10/19 00:00 [revised]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/12/18 06:00 [medline]
AID - 10.1111/dom.13135 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Feb;20 Suppl 1:34-46. doi: 10.1111/dom.13135.